Trial Profile
Safety, tolerability, and pharmacokinetics study of single and multiple subcutaneous doses of turoctocog alfa pegol in patients with haemophilia A
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Dec 2021
Price :
$35
*
At a glance
- Drugs Turoctocog alfa pegol (Primary)
- Indications Haemophilia A
- Focus Adverse reactions
- Acronyms alleviate 1
- Sponsors Novo Nordisk
- 16 Oct 2019 Results published in the Journal of Thrombosis and Haemostasis.
- 16 Oct 2018 Status changed from active, no longer recruiting to completed.
- 05 Jul 2018 Status changed from recruiting to active, no longer recruiting.